Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04637334 · ClinicalTrials.gov registry record
Superior Vena Cava Reconstruction in Patients on Hemodialysis
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 45
- Enrollment target
NCT04637334 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 45 participants.
The verdict
NCT04637334 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The treatment objective for patients with SVC syndrome secondary to both malignant and benign etiologies is to reduce the elevated central venous pressures.1 However, the strategies are contingent upon the underlying disease process. Thus the management of SVC syndrome ranges from medical or supportive care to surgical bypass,3 and it is important for physicians to understand the varied treatment modalities of this potentially life-threatening disease.17 Fortunately, the overwhelming majority of patients with SVC syndrome secondary to benign causes develop a physiologic compensation for the obstruction that can be treated with anticoagulation and endovascular modalities. Intervention for symptomatic relief may not be required.1 An endovascular approach is the current standard of care to relieve SVC obstruction due to malignancy to obtain prompt relief of the rapidly emerging symptoms and improve quality of life,3 keeping in mind the short life expectancy of these patients. The role of endovascular therapy in SVC syndrome of nonmalignant etiology is undecided because the long-term durability of this treatment method remains to be assessed.
Interventions
- PROCEDURE Superior vena cava reconstruction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-09-13 |
| Est. Completion | 2022-05-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04637334
The ClinicalTrials.gov registry entry for NCT04637334 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Superior vena cava reconstruction is the first listed.
NCT04637334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04637334 about?
NCT04637334 is a clinical study titled "Superior Vena Cava Reconstruction in Patients on Hemodialysis". The treatment objective for patients with SVC syndrome secondary to both malignant and benign etiologies is to reduce the elevated central venous pressures.1 However, the strategies are contingent upon the underlying disease process. Thus the management of SVC syndrome ranges from medical or support...
What is the current status of trial NCT04637334?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2014-09-13. Estimated completion is 2022-05-06.
What interventions are being tested in trial NCT04637334?
The interventions under investigation include: Superior vena cava reconstruction (PROCEDURE).
Who is sponsoring clinical trial NCT04637334?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.